Source: Eur Respir J 2011; 38: 1105-1116
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Leclercq S., Gueugnon F., Boutin B., Guillot F., Blanquart C., Rogel A., Padieu M., Pouliquen D., Fonteneau J-F., Grégoire M.. A 5-aza-2?-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur Respir J 2011; 38: 1105-1116

Member's Comments

No comment yet.

Related content which might interest you: Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Source: Eur Respir J 2009; 34: 145-155 Year: 2009 Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study Source: Eur Respir J 2011; 37: 129-135 Year: 2011 Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models Source: ERJ Open Res 2015; 1: 00028-2015 Year: 2015 Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice Source: Eur Respir J 2009; 34: 1159-1167 Year: 2009 VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study Source: ERJ Open Res 2015; 1: 00029-2015 Year: 2015 Ursodeoxy cholic acid (UDCA) reverses hepatotoxicity of multidrug treatment of mycobacterial infections Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018 Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001 Folic acid phenotype (FAP) as superior marker to predict pemetrexed response in pleural mesothelioma Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside Year: 2016 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Recognition of pleural mesothelioma by mucin-1(950–958)/human leukocyte antigen A*0201-specific CD8+ T-cells Source: Eur Respir J 2011; 38: 1117-1126 Year: 2011 2-Deoxy-glucose synergizes with Cisplatin and Pemetrexed chemotherapeutics to reduce cell migration of mesothelioma cells Source: International Congress 2019 – Pleural disease: applying the evidence Year: 2019 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb) Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006 Rosmarinic acid enhances apoptosis and cell cycle arrest induced by Carnosic acid on Human Lung Fibroblasts Source: International Congress 2017 – Rare diseases Year: 2017 Differential actions of the endogenous docosahexaenoic acid (DHA) electrophilic derivative 17-oxo-DHA in macrophages and bronchial epithelial cells Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013 Retinoic acid induces alveolar regeneration in the adult mouse lung Source: Eur Respir J 2004; 23: 20-27 Year: 2004 Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Stimulation with polyinosinic-polycytidylic acid (poly(I:C)) encapsulated within novel pH-sensitive switchable liposomes leads to a faster and more potent interferon response Source: International Congress 2016 – Pulmonary drug delivery Year: 2016